| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) |
|---|---|---|---|
| AstraZeneca | Alexion Pharmaceuticals | 12 Dec 2020 | 39,000.0 |
| The Carlyle Group ., The Blackstone Group , GIC Pvt , Hellman & Friedman | Medline Industries | 05 Jun 2021 | 34,000.0 |
| Thermo Fisher Scientific | PPD | 15 Apr 2021 | 20,900.0 |
| Bristol-Myers Squibb | MyoKardia | 05 Oct 2020 | 13,100.0 |
| ICON | PRA Health Sciences | 24 Feb 2021 | 12,000.0 |
| Danaher | Aldevron | 17 Jun 2021 | 9,600.0 |
| Undisclosed Bidder | Parexel International | 20 Apr 2021 | 9,000.0 |
| Goldman Sachs Asset Management , EQT Partners | Parexel International | 02 Jul 2021 | 8,500.0 |
| Agnafit Bidco | Swedish Orphan Biovitrum | 02 Sep 2021 | 8,047.6 |
| Jazz Pharmaceuticals | GW Pharmaceuticals | 03 Feb 2021 | 7,200.0 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 9 |
| Morgan Stanley | 2 | 1 |
| The Goldman Sachs Group | 3 | 4 |
| Bank of America Corp | 4 | 10 |
| JPMorgan Chase & Co | 5 | 20 |
| Evercore | 6 | 3 |
| Lazard | 7 | 18 |
| Ondra | 8 | 68 |
| Cowen | 9 | 19 |
| J.P. Morgan Securities | 10 | 2 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Jefferies | 1 | 8 |
| The Goldman Sachs Group | 2 | 2 |
| Cowen | 3 | 33 |
| Centerview Partners | 4 | 4 |
| Bank of America Corp | 5 | 9 |
| SVB Financial Group | 6 | 12 |
| Morgan Stanley | 7 | 1 |
| Evercore | 8 | 7 |
| Rothschild & Co SCA | 9 | 5 |
| Barclays Plc | 10 | 23 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Wachtell, Lipton, Rosen & Katz | 1 | 3 |
| Fried, Frank, Harris, Shriver & Jacobson | 2 | 19 |
| Goodwin Procter | 3 | 20 |
| Freshfields Bruckhaus Deringer | 4 | 16 |
| Allen & Overy | 5 | 62 |
| Latham & Watkins | 6 | 21 |
| Simmons & Simmons | 7 | 173 |
| Sullivan & Cromwell | 8 | 15 |
| Davis Polk & Wardwell | 9 | 2 |
| Cravath, Swaine & Moore | 10 | 18 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Goodwin Procter | 1 | 2 |
| Wilson Sonsini Goodrich & Rosati | 2 | 23 |
| Latham & Watkins | 3 | 1 |
| Cooley | 4 | 5 |
| Ropes & Gray | 5 | 7 |
| Kirkland & Ellis | 6 | 4 |
| Baker & McKenzie | 7 | 12 |
| Morgan, Lewis & Bockius | 8 | 15 |
| Jones Day | 9 | 3 |
| Dechert | 10 | 54 |
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | AstraZeneca | Alexion Pharmaceuticals | 12 Dec 2020 | 39,000.0 | Thermo Fisher Scientific | PPD | 15 Apr 2021 | 20,900.0 | Bristol-Myers Squibb | MyoKardia | 05 Oct 2020 | 13,100.0 | ICON | PRA Health Sciences | 24 Feb 2021 | 12,000.0 | Danaher | Aldevron | 17 Jun 2021 | 9,600.0 | Agnafit Bidco | Swedish Orphan Biovitrum | 02 Sep 2021 | 8,047.6 | Jazz Pharmaceuticals | GW Pharmaceuticals | 03 Feb 2021 | 7,200.0 | Humana | Kindred Healthcare | 27 Apr 2021 | 5,700.0 | PerkinElmer | Biolegend | 26 Jul 2021 | 5,250.0 | CBPO Holdings | China Biologic Products Holdings | 19 Nov 2020 | 4,760.0 |
|---|
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 9 |
| Morgan Stanley | 2 | 1 |
| The Goldman Sachs Group | 3 | 4 |
| Bank of America Corp | 4 | 12 |
| JPMorgan Chase & Co | 5 | 20 |
| Evercore | 6 | 3 |
| Lazard | 7 | 15 |
| Ondra | 8 | 50 |
| Cowen | 9 | 17 |
| Mizuho Financial Group | 10 | N/A |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Centerview Partners | 1 | 4 |
| The Goldman Sachs Group | 2 | 2 |
| Bank of America Corp | 3 | 6 |
| Jefferies | 4 | 5 |
| Lazard | 5 | 3 |
| Morgan Stanley | 6 | 1 |
| JPMorgan Chase & Co | 7 | 23 |
| Evercore | 8 | 8 |
| Cowen | 9 | 35 |
| Barclays Plc | 10 | 22 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Wachtell, Lipton, Rosen & Katz | 1 | 3 |
| Fried, Frank, Harris, Shriver & Jacobson | 2 | 18 |
| Goodwin Procter | 3 | 19 |
| Freshfields Bruckhaus Deringer | 4 | 20 |
| Allen & Overy | 5 | 65 |
| Simmons & Simmons | 6 | 126 |
| Sullivan & Cromwell | 7 | 15 |
| Latham & Watkins | 8 | 22 |
| Davis Polk & Wardwell | 9 | 2 |
| Cravath, Swaine & Moore | 10 | 17 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Goodwin Procter | 1 | 1 |
| Cooley | 2 | 3 |
| Morgan, Lewis & Bockius | 3 | 12 |
| Latham & Watkins | 4 | 2 |
| Wilson Sonsini Goodrich & Rosati | 5 | 16 |
| White & Case | 6 | 23 |
| Skadden, Arps, Slate, Meagher & Flom & Affiliates | 7 | 4 |
| Ropes & Gray | 8 | 15 |
| Gibson, Dunn & Crutcher | 9 | 22 |
| Kirkland & Ellis | 10 | 6 |
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | The Carlyle Group ., The Blackstone Group , GIC Pvt , Hellman & Friedman | Medline Industries | 05 Jun 2021 | 34,000.0 | Undisclosed Bidder | Parexel International | 20 Apr 2021 | 9,000.0 | Goldman Sachs Asset Management , EQT Partners | Parexel International | 02 Jul 2021 | 8,500.0 | Permira Advisers | LivaNova | 04 Mar 2021 | 3,700.0 | CVC Capital Partners Fund VII, Avista Capital Partners (Avista Capital Holdings, ) | Cooper Consumer Health | 12 Mar 2021 | 2,600.0 | EQT IX Fund | Recipharm | 14 Dec 2020 | 2,116.9 | Nordic Capital | Advanz Pharma | 27 Jan 2021 | 1,920.1 | Partners Group | Pharmathen | 19 Jul 2021 | 1,888.7 | Altaris Capital Partners | Generic Rx Pharma Business | 01 Mar 2021 | 1,550.0 | Pamplona Capital Management , Triton Investment Management Limited, CVC Capital Partners SICAV-FIS SA, Bain Capital , BC Partners | Mediq | 21 Oct 2020 | 1,416.3 |
|---|
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Rothschild & Co SCA | 1 | 1 |
| Deloitte Touche Tohmatsu | 2 | 23 |
| Carnegie Holding AB | 3 | N/A |
| Goldman Sachs International | 4 | N/A |
| Jefferies International | 5 | N/A |
| Ernst & Young Global | 6 | 31 |
| PricewaterhouseCoopers International | 7 | 2 |
| UBS Group AG | 8 | 3 |
| Jefferies | 9 | 50 |
| Evercore | 10 | 15 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Jefferies | 1 | 51 |
| SVB Financial Group | 2 | 37 |
| Rothschild & Co SCA | 3 | 2 |
| Carnegie Holding AB | 4 | N/A |
| Cowen | 5 | N/A |
| Deloitte Touche Tohmatsu | 6 | 7 |
| Evercore | 7 | 6 |
| Barclays Plc | 8 | 16 |
| Van Lanschot Kempen NV | 9 | N/A |
| Ernst & Young Global | 10 | 9 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Ropes & Gray | 1 | 17 |
| Latham & Watkins | 2 | 10 |
| Uria Menendez Abogados S | 3 | N/A |
| Goodwin Procter | 4 | 28 |
| Clifford Chance | 5 | 41 |
| Roschier Attorneys | 6 | 38 |
| Setterwalls Advokatbyra AB | 7 | N/A |
| Allen & Overy | 8 | 56 |
| Linklaters | 9 | 5 |
| Ashurst | 10 | 7 |
| Advisor Name | 2020 Rank | 2019 Rank |
|---|---|---|
| Latham & Watkins | 1 | 1 |
| Goodwin Procter | 2 | 36 |
| Ropes & Gray | 3 | 3 |
| Uria Menendez Abogados S | 4 | N/A |
| Baker & McKenzie | 5 | N/A |
| Kirkland & Ellis | 6 | 2 |
| DLA Piper | 7 | N/A |
| Sidley Austin | 8 | 19 |
| Dechert | 9 | 35 |
| Paul, Weiss, Rifkind, Wharton & Garrison | 10 | 16 |
| Acquirer/Investor | Issuer / Partner / Target | Deal Date | Value (US$m) | GV Management , New Enterprise Associates , 8VC, ARCH Venture Partners | National Resilience | 23 Nov 2020 | 750.0 | Temasek Holdings (Private) , Lilly Asia ventures, GL Ventures | Suzhou Abogen Biosciences | 19 Aug 2021 | 700.0 | Itochu Technology Ventures, ., Emerson Collective , Invus Group , EcoR1 Capital , Vertex Ventures HC, F2 Ventures Limited, Matrix Capital Management Fund , Surveyor Capital , SoftBank Vision Fund , Redmile Group , Fidelity Management & Research Company, EDBI Pte , Samsara BioCapital , MPM Capital | ElevateBio | 15 Mar 2021 | 525.0 | SignalFire Management Services, , Radcliff Group, Baupost Group, FirstMark Capital , Altimeter Capital Management , TQ Ventures , General Catalyst Partners , BoxGroup, ShawSpring Partners, , Torch Capital, Dragoneer Investment Group , 776 Fund Management | Ro-co | 23 Mar 2021 | 500.0 | Andreessen Horowitz , Nextech Invest , Casdin Capital , ARCH Venture Partners , Section 32, Arboretum Ventures , GV Management | EQRx | 11 Jan 2021 | 500.0 | Federated Hermes , BlackRock , Flagship Pioneering , Canada Pension Plan Investment Board, Fidelity Management & Research Company, Invus , T Rowe Price Associates | Laronde | 30 Aug 2021 | 440.0 | Sino Biopharmaceutical , 5Y Capital, Orbimed Advisors , Sequoia Capital Operations , RRJ Capital | XtalPi | 11 Aug 2021 | 400.0 | Temasek Holdings (Private) , Two Sigma Ventures , GV Management , Alexandria Venture Investments, Foresite Capital Management , Third Rock Ventures , SoftBank Investment Advisors, BlackRock , T Rowe Price Associates , Andreessen Horowitz , ARCH Venture Partners , Canada Pension Plan Investment Board, Casdin Capital , HOF Capital | Insitro | 15 Mar 2021 | 400.0 | Premji Invest, Orbimed Advisors , Population Health Partners , GV Management , Foresite Capital Management , Federated Hermes , Mithril Capital Management , Redmile Group , RA Capital Management , Polaris Partners , ArrowMark Partners, Adimab , Fidelity Management & Research Company, Omega Fund Management | Adagio Therapeutics | 19 Apr 2021 | 336.0 | Central Enterprise Poverty Area Industrial Investment Fund , China Merchants Securities , Tianjin Liren Investment Management, Huatai Securities | Shenzhen Huada Gene | 09 Feb 2021 | 310.3 |
|---|
All markets data shared in the dashboard is copyright of GlobalData PLC and is subject to the GlobalData Terms & Conditions. Content in the dashboard should not be viewed as a recommendation and should not be relied upon to make investment decisions. We make every effort to ensure our content is accurate and to correct mistakes as soon as possible. If you spot an error please email editorialenquiries@globaldata.com. Further information about our editorial standards and complaints procedure is available here. GlobalData is not responsible for the use of any content outside the scope of the GlobalData Terms & Conditions.
Otsuka Pharmaceutical subsidiary Astex Pharmaceuticals has reported updated clinical results from the Phase III ASCERTAIN clinical trial of Inqovi in adults with intermediate and high-risk…
Valneva has initiated recruitment of adolescent subjects in the pivotal Phase III Cov-Compare (VLA2001-301) clinical trial of its inactivated Covid-19 vaccine candidate, VLA2001, in the…
Appili Therapeutics has concluded subject enrolment in its international Phase III PRESECO clinical trial of oral Avigan/Reeqonus (favipiravir) as a…
Inovio is set to commence the Phase III segment of its international Phase II/III INNOVATE clinical trial of its Covid-19…
pHOXBIO has reported data from a pivotal Phase II/III clinical trial that showed that its new prophylactic nasal spray, pHOXWELL,…
PathAI and Summit Clinical Research have partnered to offer an integrated clinical trial services solution for non-alcoholic steatohepatitis (NASH) drug…
GlobalData exists to help businesses decode the future to profit from faster, more informed decisions.
© Copyright Verdict Media Limited 2021
